Emtora Biosciences is a life science company developing a novel formulation of rapamycin, eRapa™, for use in preventing the onset and recurrence of cancer. A Phase 1b safety and dosing clinical trial is underway in early stage prostate cancer patients. A pilot efficacy study in Familial Adenomatous Polyposis (FAP) is planned for late 2019.